TARS - Tarsus Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Irvine,
United States
Type: Equity
TARS price evolution
TARS
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $181.09 | $193.71 | $224.95 | |
| Short term investments | $142.49 | $104.82 | $2.5 | |
| Net receivables | $30.3 | $30.84 | $31.36 | $17.71 |
| Inventory | $2.85 | $4.73 | $4.04 | $3.11 |
| Total current assets | $357.12 | $362.59 | $340.72 | $256.13 |
| Long term investments | $3 | $0.63 | ||
| Property, plant & equipment | $4.2 | $4.21 | $3.47 | $3.35 |
| Goodwill & intangible assets | $3.67 | $3.77 | $3.87 | |
| Total noncurrent assets | $14.26 | $8.55 | $9.36 | |
| Total investments | $145.49 | $104.82 | $3.13 | |
| Total assets | $376.3 | $376.84 | $349.28 | $265.49 |
| Current liabilities | ||||
| Accounts payable | $26.82 | $43.53 | $36.57 | $23.69 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $65.87 | $51.57 | $42.53 | $36.94 |
| Long term debt | $71.71 | $71.58 | $29.93 | $29.82 |
| Total noncurrent liabilities | $73.03 | $31.54 | $31.57 | |
| Total debt | $71.58 | $29.93 | $29.82 | |
| Total liabilities | $138.82 | $124.6 | $74.07 | $68.5 |
| Shareholders' equity | ||||
| Retained earnings | -$337.1 | -$313.68 | -$280.39 | -$244.66 |
| Other shareholder equity | $0.35 | -$0.18 | -$0.06 | -$0 |
| Total shareholder equity | $252.25 | $275.21 | $196.99 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $224.95 | $71.66 | $171.33 | $168.15 |
| Short term investments | $2.5 | $145.37 | $0.48 | |
| Net receivables | $17.71 | $3.58 | $0.09 | $0.02 |
| Inventory | $3.11 | |||
| Total current assets | $256.13 | $225.38 | $175.95 | $170.7 |
| Long term investments | $0.63 | $0.37 | ||
| Property, plant & equipment | $3.35 | $1.53 | $1.83 | $1.2 |
| Goodwill & intangible assets | $3.87 | |||
| Total noncurrent assets | $9.36 | $2.49 | $2.96 | $1.32 |
| Total investments | $3.13 | $145.74 | $0.48 | |
| Total assets | $265.49 | $227.86 | $178.91 | $172 |
| Current liabilities | ||||
| Accounts payable | $23.69 | $9.91 | $2.86 | $2.2 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $36.94 | $15.43 | $11.48 | $5.4 |
| Long term debt | $29.82 | $19.43 | ||
| Total noncurrent liabilities | $31.57 | $19.53 | $0.7 | $0.6 |
| Total debt | $29.82 | $19.43 | ||
| Total liabilities | $68.5 | $34.96 | $12.18 | $6 |
| Shareholders' equity | ||||
| Retained earnings | -$244.66 | -$108.76 | -$46.67 | -$32.8 |
| Other shareholder equity | -$0 | -$0.07 | ||
| Total shareholder equity | $196.99 | $192.9 | $166.73 | $165.98 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $48.12 | $40.81 | $27.61 | $13.08 |
| Cost of revenue | $3 | $1.65 | $1.22 | |
| Gross Profit | $44.88 | $37.81 | $25.96 | $11.86 |
| Operating activities | ||||
| Research & development | $12.32 | $12.07 | $13.3 | |
| Selling, general & administrative | $58.79 | $51.58 | $43.01 | |
| Total operating expenses | $70.04 | $71.11 | $63.64 | $56.31 |
| Operating income | -$33.3 | -$37.68 | -$44.45 | |
| Income from continuing operations | ||||
| EBIT | -$31.18 | -$34.75 | -$40.91 | |
| Income tax expense | ||||
| Interest expense | $1.68 | $2.11 | $0.98 | $0.99 |
| Net income | ||||
| Net income | -$23.42 | -$33.29 | -$35.73 | -$41.9 |
| Income (for common shares) | -$33.29 | -$35.73 | -$41.9 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $17.45 | $25.82 | $57.03 | |
| Cost of revenue | $1.59 | $0.95 | $2.08 | |
| Gross Profit | $15.85 | $24.86 | $54.95 | |
| Operating activities | ||||
| Research & development | $50.31 | $42.62 | $41.71 | $18.83 |
| Selling, general & administrative | $108.7 | $44.95 | $25.4 | $8.17 |
| Total operating expenses | $159.01 | $87.57 | $67.11 | $27 |
| Operating income | -$143.16 | -$62.71 | -$12.16 | -$27 |
| Income from continuing operations | ||||
| EBIT | -$132.55 | -$59.9 | -$13.77 | -$26.62 |
| Income tax expense | -$0 | $0.06 | $0 | |
| Interest expense | $3.35 | $2.2 | $0.19 | |
| Net income | ||||
| Net income | -$135.89 | -$62.09 | -$13.83 | -$26.81 |
| Income (for common shares) | -$135.89 | -$62.09 | -$13.83 | -$26.81 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$33.29 | -$35.73 | -$41.9 | |
| Operating activities | ||||
| Depreciation | $0.4 | $0.4 | $0.48 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.48 | $5.52 | $5.48 | |
| Total cash flows from operations | -$14.4 | -$37.79 | -$39.34 | |
| Investing activities | ||||
| Capital expenditures | -$1.04 | -$0.17 | ||
| Investments | -$39.49 | -$102.05 | $17.85 | |
| Total cash flows from investing | -$139.62 | -$40.52 | -$102.22 | $17.85 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.68 | $108.77 | $19.76 | |
| Net borrowings | $39.64 | |||
| Total cash flows from financing | $151.73 | $42.32 | $108.77 | $19.76 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$48.74 | -$12.61 | -$31.24 | -$1.73 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$135.89 | -$62.09 | -$13.83 | -$26.81 |
| Operating activities | ||||
| Depreciation | $1.42 | $0.79 | $0.61 | $0.25 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $19.83 | $13.46 | $8.46 | $0.84 |
| Total cash flows from operations | -$117.49 | -$49.03 | $3.75 | -$21.14 |
| Investing activities | ||||
| Capital expenditures | -$5.5 | -$0.51 | -$0.59 | -$0.46 |
| Investments | $146.11 | -$144.12 | ||
| Total cash flows from investing | $140.6 | -$144.63 | -$0.59 | -$0.46 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $120.18 | $74.94 | $0.32 | $92.04 |
| Net borrowings | $10 | $19.13 | ||
| Total cash flows from financing | $130.18 | $93.99 | $0.02 | $131.77 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $153.29 | -$99.67 | $3.18 | $110.18 |
News
Fundamentals
| Market cap | $2.52B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 38.20M |
| Revenue | $129.62M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$134.34M |
| Revenue Q/Q | 2.47K% |
| Revenue Y/Y | 801.96% |
| P/E ratio | -18.78 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 19.47 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$3.52 |
|---|---|
| ROA | -39.28% |
| ROE | N/A |
| Debt/Equity | 0.35 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.42 |
| Quick ratio | 5.38 |